<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344461</url>
  </required_header>
  <id_info>
    <org_study_id>H-23783</org_study_id>
    <nct_id>NCT00344461</nct_id>
  </id_info>
  <brief_title>A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine</brief_title>
  <official_title>Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and
      Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy
      will be enrolled. Study will include a pharmacokinetic substudy to evaluate the interaction
      of FTC and Nevirapine. Truvada may be used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of study design This is an open-labeled clinical trial evaluating an
      antiretroviral treatment regimen in which the drugs have demonstrated in vitro activity in
      both, resting and activated mononuclear cells. These drugs include: FTC 200 mg p.o. qd, and
      Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.

      Eligible patients must be at least 18 years of age, be referred by their primary HIV provider
      for antiretroviral therapy or if the patient is self referred, have a cluster of
      differentiation 4 (CD4) cell count of &lt; 250/mm3 and have a viral load &gt;5,000c/ml. Eligibility
      requirement for women is that they must have a CD4 cell count of &lt;250 at the time of
      enrollment. This cutoff for women is based on unpublished data that there may be increased
      hepatotoxicity in women with a CD4 cell count &gt; 250 cell/mm3. The screening evaluation will
      take place the day the informed consent is signed. During that screening evaluation, the
      patient will undergo a history and physical examination, and will have study labs drawn.
      Within 60 days of the screening evaluation and meeting all eligible criteria, the patient
      will be placed on the study treatment regimen. Patients will be evaluated at the clinic on
      Day 0 (therapy initiation), weeks 2, 4, 6, 8, 12, 16, and then every 8 weeks until 48 weeks
      and thereafter every 12 weeks through week 96. At the end of the study, all patients may
      continue their current antiretroviral treatment regimen at the discretion of the patient and
      their primary care provider.

      Pharmacokinetic Analysis Sub Study A pharmacokinetic evaluation will be performed in first 7
      volunteers to assess the impact of FTC on Nevirapine and vice versa. Pharmacokinetic analysis
      will be performed at end of week 2 ( day 14) during 200mg qd start up period. Samples will be
      obtained at baseline and 1, 3, 6, 12 and 24 hours post Nevirapine dosing. Pharmacokinetic
      analysis will be repeated at the week 8 visit. Samples will be obtained at baseline and 1, 3,
      6, 12 and 24 hours post Nevirapine.

      Assignment of patients There will be 60 patients involved in this clinical trial. This is an
      open-labeled study. There are no placebos involved in this study.

      Dose and dose selection The dosages of medications are those that are currently used as
      standard clinical practice: Nevirapine 200 mg b.i.d. (1-200 mg tablet b.i.d.); Emtricitabine
      (FTC) 200mg po qd.(1-200mg capsule); Tenofovir 300 mg once-a-day (1-300 mg tablet qd).

      Justification of study design All study patients require treatment for their HIV infection.
      All of the drugs used in this study are FDA-Approved. Tenofovir and FTC are approved as a
      once-a-day treatment medication. Nevirapine (NVP) is approved for BID dosing.

      NOTE: That whenever Nevirapine is being prescribed, there will be a lead-in period of 14 days
      in which Nevirapine will be prescribed as 200 mg once a day followed by 200 mg BID as is the
      recommended standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Virologic Response</measure>
    <time_frame>96 Weeks</time_frame>
    <description>The primary outcome is sustained Virologic response, defined as HIV-1 RNA &lt;500 copies/mL until trial completion at 96 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade 2, 3 and 4 Adverse Events and Laboratory Toxicities</measure>
    <time_frame>Protocol length is 96 weeks</time_frame>
    <description>The number of participants with grades 2,3 and 4 adverse events and laboratory toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Plasma HIV RNA &lt; 50 Copies/mL</measure>
    <time_frame>96 weeks.</time_frame>
    <description>The number of participants with plasma HIV RNA &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Plasma HIV RNA &lt; 400 Copies/mL</measure>
    <time_frame>96 weeks</time_frame>
    <description>The number of participants with plasma HIV RNA &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma HIV RNA From Baseline to Week 96</measure>
    <time_frame>Baseline to week 96</time_frame>
    <description>Percent Change From Baseline in Plasma HIV RNA at 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 Cell Count From Baseline and Week 96</measure>
    <time_frame>Baseline to week 96</time_frame>
    <description>To determine the mean change from Baseline in CD4 cell count to week 96.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Nevirapine, FTC, Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine, FTC, and Tenofovir</intervention_name>
    <description>One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.</description>
    <arm_group_label>Nevirapine, FTC, Tenofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection, as documented by any licensed ELISA test kit, and confirmed by
             Western blot, positive HIV-1 blood culture, positive HIV serum antigen, or plasma
             viremia at any time prior to study entry. If no record exists, testing must occur at
             screening.

          2. Male or female, age 18 to 75 years of age.

          3. Able to sign the informed consent, and is willing to comply with the requirements of
             this clinical trial.

          4. Available for at least 96 weeks of follow up.

          5. Males: deemed a candidate for antiretroviral therapy per referring primary care
             provider. (If patient is self referred, CD4 cell count must be &lt;400 cells/mm3 and
             viral load&gt;5,000c/ml) Females: CD4 cell count must be less than 250 cells/mm3 and
             viral load &gt;5,000 c/mL at time of enrollment.

          6. If female and of child bearing potential must consent to using at least two forms of
             contraception.

          7. Participants will be &quot;treatment naive&quot; as no prior antiretroviral therapy or
             antiretroviral therapy for less than 7 days in the past.

        Exclusion Criteria:

          1. Evidence of mutation associated with primary drug resistance to Nevirapine (K103N,
             Y181C, Y188L, G190S), Tenofovir (M41L, T69 insertion, Q151M, L210W,and K65R), and/or
             FTC (184V) previously documented, or at time of screening.

          2. Patients with any of the following laboratory parameters at the screening visit:
             estimated creatinine clearance of &lt;60 ml/min; aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) &gt;2.5 times the upper limits of normal; total bilirubin
             &gt;1.5 mg/dL.

          3. Women with CD4 cell count &gt; 250 cells/ mm3 at time of entry or in males with a CD4
             cell count less than 400/mm3, along with a viral load greater than 5,000c/ml. for both
             males and females.

          4. Pregnant women or women who are breast feeding.

          5. Unwillingness to use effective barrier contraception.

          6. Patients with current alcohol abuse or illicit drug use that in the opinion of the
             Principal Investigator may interfere with the patient's ability to comply with the
             protocol requirements.

          7. Patients with malabsorption or severe chronic diarrhea for more than 30 days.

          8. Current treatment for malignancy other than basal or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix.

          9. History of any chronic illness or other condition that in the opinion of the
             investigator would interfere with the conduct or completion of the study.

         10. Patient who is, in the opinion of the investigator, unable to complete the 96-week
             dosing period and protocol evaluations and assessments.

         11. Experimental vaccines, to include HIV vaccines.

         12. Patient who is currently enrolled in an experimental protocol, or is receiving an
             experimental medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Redfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, School of Medicine, IHV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles E Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, School of Medicine, IHV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <results_first_submitted>October 2, 2015</results_first_submitted>
  <results_first_submitted_qc>October 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2017</results_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Charles E. Davis, Jr.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Group (TDF/FTC &amp; NVP)</title>
          <description>To evaluate the long-term antiviral activity of a three cell cycle independent reverse transcriptase regimen consisting of Nevirapine 200mg twice-a-day, Tenofovir 300mg and Emtricitabine 200mg once-a-day in the treatment of patients with chronic HIV infection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF, FTC &amp; NVP</title>
          <description>To evaluate the long-term antiviral activity of a three cell cycle independent reverse transcriptase regimen consisting of Nevirapine 200mg twice-a-day, Tenofovir 300mg and Emtricitabine 200mg once-a-day in the treatment of patients with chronic HIV infection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Virologic Response</title>
        <description>The primary outcome is sustained Virologic response, defined as HIV-1 RNA &lt;500 copies/mL until trial completion at 96 weeks.</description>
        <time_frame>96 Weeks</time_frame>
        <population>HIV-1 infected Males: cluster of differentiation 4 (CD4) cell count less than 400 cells/mm3 and viral load greater than 5,000c/ml) Females: CD4 cell count less than 250 cells/mm3 and viral load greater than 5,000 c/mL at time of enrollment. Treatment naive</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group (TDF/FTC &amp; NVP)</title>
            <description>To evaluate the long-term antiviral activity of a three cell cycle independent reverse transcriptase regimen consisting of Nevirapine 200mg twice-a-day, Tenofovir 300mg and Emtricitabine 200mg once-a-day in the treatment of patients with chronic HIV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virologic Response</title>
          <description>The primary outcome is sustained Virologic response, defined as HIV-1 RNA &lt;500 copies/mL until trial completion at 96 weeks.</description>
          <population>HIV-1 infected Males: cluster of differentiation 4 (CD4) cell count less than 400 cells/mm3 and viral load greater than 5,000c/ml) Females: CD4 cell count less than 250 cells/mm3 and viral load greater than 5,000 c/mL at time of enrollment. Treatment naive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade 2, 3 and 4 Adverse Events and Laboratory Toxicities</title>
        <description>The number of participants with grades 2,3 and 4 adverse events and laboratory toxicities.</description>
        <time_frame>Protocol length is 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine, FTC, Tenofovir</title>
            <description>Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
Nevirapine, FTC, and Tenofovir: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade 2, 3 and 4 Adverse Events and Laboratory Toxicities</title>
          <description>The number of participants with grades 2,3 and 4 adverse events and laboratory toxicities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Plasma HIV RNA &lt; 50 Copies/mL</title>
        <description>The number of participants with plasma HIV RNA &lt; 50 copies/mL</description>
        <time_frame>96 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group (TDF/FTC &amp; NVP)</title>
            <description>To evaluate the long-term antiviral activity of a three cell cycle independent reverse transcriptase regimen consisting of Nevirapine 200mg twice-a-day, Tenofovir 300mg and Emtricitabine 200mg once-a-day in the treatment of patients with chronic HIV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Plasma HIV RNA &lt; 50 Copies/mL</title>
          <description>The number of participants with plasma HIV RNA &lt; 50 copies/mL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Plasma HIV RNA &lt; 400 Copies/mL</title>
        <description>The number of participants with plasma HIV RNA &lt; 400 copies/mL</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine, FTC, Tenofovir</title>
            <description>Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
Nevirapine, FTC, and Tenofovir: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Plasma HIV RNA &lt; 400 Copies/mL</title>
          <description>The number of participants with plasma HIV RNA &lt; 400 copies/mL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma HIV RNA From Baseline to Week 96</title>
        <description>Percent Change From Baseline in Plasma HIV RNA at 96 weeks</description>
        <time_frame>Baseline to week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine, FTC, Tenofovir</title>
            <description>Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
Nevirapine, FTC, and Tenofovir: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma HIV RNA From Baseline to Week 96</title>
          <description>Percent Change From Baseline in Plasma HIV RNA at 96 weeks</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread=".043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CD4 Cell Count From Baseline and Week 96</title>
        <description>To determine the mean change from Baseline in CD4 cell count to week 96.</description>
        <time_frame>Baseline to week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine, FTC, Tenofovir</title>
            <description>Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
Nevirapine, FTC, and Tenofovir: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Cell Count From Baseline and Week 96</title>
          <description>To determine the mean change from Baseline in CD4 cell count to week 96.</description>
          <units>percentage of CD4 Increase</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252" spread="89.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <desc>A written report will be filed with the Institutional Review Board (IRB) within 5 working days for serious adverse event and annually for all others.</desc>
      <group_list>
        <group group_id="E1">
          <title>FTC, TDF, &amp; NVP</title>
          <description>To evaluate the long-term antiviral activity of a three cell cycle independent reverse transcriptase regimen consisting of Nevirapine 200mg twice-a-day, Tenofovir 300mg and Emtricitabine 200mg once-a-day in the treatment of patients with chronic HIV infection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrapenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Malignant Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CMV Retinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 &amp; 4 Liver Function Test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Grade 4 alanine aminotransferase (ALT) test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diffused Lung Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Stevens Johnson</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Right Femoral Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster Othalmicus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Preseptal Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncopy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Drug Detoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Left Hand Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Stabbing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess Right Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles E. Davis, Jr., MD</name_or_title>
      <organization>University of Maryland, Institute Of Human Virology</organization>
      <phone>410-706-4608</phone>
      <email>cdavis@ihv.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

